PAREXEL International Corporation (NASDAQ:PRXL) will release the first quarter earnings for 2010 on Tuesday, October 27. The company will host a conference call at 10:00 am ET the following day, Wednesday, October 28, to discuss the financial results. Interested parties may access the call by dialing 706.758.4950 and asking for the PAREXEL’s First Quarter Fiscal Year 2010 Conference Call. A webcast of the conference will be on the Investor Relations section of the company’s website, http://www.parexel.com/.
Get Rich Penny Stocks is a leading financial publication that is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications services, consulting, and informatics and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries. The company has three business segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics, Inc. (Perceptive). CRS service offerings include clinical trials management and biostatistics, data management and clinical pharmacology, patient recruitment, and investigator site services. PCMS provides technical expertise and advice in such areas as drug development, regulatory affairs, and good manufacturing practice compliance consulting. Perceptive provides information technology solutions designed to improve clients’ product development processes. In August 2008, PAREXEL acquired ClinPhone plc.
Sign up for the Free GetRichPennyStocks Newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
GetRichPennyStocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that could be on the brink of a breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
